In this cross-sectional study at Farabi Eye Hospital in Tehran, Iran, 38 consecutive patients with PXS and 37 normal volunteers who were examined for healthy eye and/or refractive check-ups were enrolled. In cases where both eyes of the patient met the eligibility criteria for the study, only one eye was randomly chosen for inclusion. All participants underwent a complete ophthalmic examination, including measurement of best-corrected visual acuity (Early Treatment Diabetic Retinopathy Study chart), slit-lamp biomicroscopy, Goldmann applanation tonometry, gonioscopy, dilated stereoscopic fundus examination using a 90 or 78 diopter (D) lens, measurement of the central corneal thickness by pachymeter (Tomey Corporation, Nagoya, Japan), a visual field test (Humphrey Field Analyzer II 750; 24-2 Swedish interactive threshold algorithm; Carl Zeiss Meditec, Dublin, CA, USA), axial length measurement (IOLMaster; Carl Zeiss Meditec), and SD-OCT imaging of the ONH and macula (Spectralis OCT, Heidelberg Engineering, Inc., Dossenheim, Germany). The inclusion criteria were (1) best-corrected visual acuity of 20/40 or better with a spherical equivalent within 5 diopters (D) and a cylinder correction within 3 D; (2) IOP < 22 mm Hg without the use of glaucoma medications; and (3) reliable Humphrey Field Analyzer results with a false-positive error rate of less than 15%, a false-negative error rate of less than 20%, and a fixation loss rate of less than 20%. The exclusion criteria included (1) any other intraocular diseases or neurologic diseases that could cause visual field loss, (2) any history of previous ocular surgery, (3) a diagnosis of glaucoma in the fellow eye, (4) significant media opacity, or (5) a history of diabetes mellitus.
The patients were enrolled into the PXS group if they possessed (1) visible pseudoexfoliation material on the anterior lens capsule or pupillary margin after mydriasis on slit-lamp, (2) having an IOP < 22 mm Hg, (3) no history of increased IOP, (4) an absence of glaucomatous disc appearance (an intact neuroretinal rim without cupping, notches, or localized pallor), and (5) a normal visual field defined by mean deviation (MD) and pattern standard deviation (PSD) within 95% confidence interval limits and a Glaucoma Hemifield Test within normal limits. The normal control group was defined as those having an IOP < 22 mm Hg, no history of increased IOP, an absence of glaucomatous disc appearance, normal standard automated perimetry results, and no evidence of pseudoexfoliation material on the anterior lens capsule or pupillary margin after mydriasis on slit-lamp in both eyes.
The study was implemented in accordance with the tenets of the Declaration of Helsinki. The study protocol was approved by the local ethics review committee of Tehran University of Medical Sciences, and all participants provided written informed consent prior to inclusion.